A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer

Acta Oncologica

Volumn 42, Issue 3, 2003, Pages 195-201

  Hamilton, Michael ^a   Dahut, William ^a   Brawley, Otis ^a   Davis, Patricia ^a   Wells Jones, Toni ^a   Kohler, David ^a   Duray, Paul ^a   Liewehr, David J ^a   Lakhani, Nehal ^a   Steinberg, Seth M ^a   Figg, William D ^a   Reed, Eddie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INFUSION; PATIENT MONITORING; TOXICITY; TUMORS;

PROSTATE CANCER;

ONCOLOGY;

TAMOXIFEN; TAMOXIFEN CITRATE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HUMAN; MALE; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; THROMBOSIS; VOMITING;

AGED; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PAIN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAMOXIFEN; TREATMENT OUTCOME; VINBLASTINE;

EID: 0037525271     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310010718     Document Type: Article

References (34)

1. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9: 295-306.
2. Rini BI, Small EJ. An update on prostate cancer. Curr Opin Oncol 2001; 13: 204-11.
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
4. Figg WD, Feuer J, Bauer KS. Management of hormone-sensitive metastatic prostate cancer. Cancer Pract 1997; 5: 258-63.
5. Goktos S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26: 162-73.
6. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999; 26: 428-38.
7. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol 2001; 28(Suppl 15): 62-6 (Aug).
8. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000; 88(Suppl 12): 3015-21.
9. Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-beta in prostate cancer. Microsc Res Tech 2001; 52: 411-9.
10. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997; 31: 61-70.
11. Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996; 2: 1255-61.
12. wafl/cipl. Prostate 1998; 37: 51-9.
13. Ritchie GL. Current therapeutics. 218. Vinblastine in malignant disease. Practitioner 1966; 196: 310-5.
14. Navarro M, Bellmunt J, Balana C, Colomer R, Jolis L, del Campo JM. Mitomycin-C and vinblastine in advanced breast cancer. Oncology 1989; 46: 137-42.
15. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000; 16: 89-111
16. Murphy GP. Review of phase II hormone refractory prostate cancer trials. Urology 1999; 54(Suppl 6A): 19-21.
17. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cacner. J Clin Oncol 1992; 10: 1754-61.
18. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1999; 84: 1811-6.
19. Pienta KJ, Replogle T, Lehr JE. Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate 1995; 26: 270-4.
20. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clnical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7.
21. Agresti A. Categorical data analysis. New York: John Wiley and Sons, 1990.
22. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989; 62: 79-87.
23. Knabbe C, Klein H, Zugmaier G, Voigt KD. Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer. J Steroid Biochem Mol Biol 1993; 47: 137-42.
24. Robertson KM, Penland SN, Padilla GM, et al. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Cell Growth Differ 1997; 8: 101-11.
25. Massague J. How cells read TGF-β signals. Nature 2000; 1: 169-78.
26. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-91.
27. Goodnight J, Mischak H, Mushinski JF. Selective involvement of protein kinase C isozymes in differentiation and neoplastic transformation. Adv Cancer Res 1994; 64: 159-209.
28. Wilding G. Response of prostate cancer cells to peptide growth factors: transforming growth factor-beta. Cancer Surv 1991; 11: 147-63.
29. Muir GH, Butta A, Shearer RJ, et al. Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 1994; 69: 130-4.
30. Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL. Blockade of transforming growth factor β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J Biol Chem 1997; 272: 8296-302.
31. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462-5.
32. Sporn MB. New agents for chemoprevention of prostate cancer. Eur Urol 1999; 35: 420-3.
33. Jordan MA, Margolis RL, Himes RH. Identification of a distinct class of vinblastine binding site on microtubules. J Mol Biol 1986; 187: 61-73.
34. Bergan RC, Reed E, Myers CE, et al. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999; 5: 2366-73.